NeuroPace, Inc. (NASDAQ:NPCE) Insider Sells $1,074,742.48 in Stock

NeuroPace, Inc. (NASDAQ:NPCE) insider Martha Morrell sold 78,334 shares of NeuroPace stock in a transaction dated Friday, February 21st. The stock was sold at an average price of $13.72, for a total value of $1,074,742.48. Following the completion of the sale, the insider now owns 81,993 shares in the company, valued at approximately $1,124,943.96. The trade was a 48.86 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Martha Morrell also recently made the following trade(s):

• On Wednesday, January 29th, Martha Morrell sold 100 shares of NeuroPace stock. The stock was sold at an average price of $15.00, for a total value of $1,500.00.
• On Friday, January 24th, Martha Morrell sold 3,200 shares of NeuroPace stock. The stock was sold at an average price of $15.01, for a total value of $48,032.00.

NeuroPace Trading Up 2.4 %

Shares of NeuroPace stock opened at $13.84 on Wednesday. The stock has a market cap of $413.10 million, a P/E ratio of -13.84 and a beta of 2.05. The stock’s 50 day simple moving average is $12.58 and its 200-day simple moving average is $9.55. NeuroPace, Inc. has a 1-year low of $5.45 and a 1-year high of $17.37. The company has a debt-to-equity ratio of 6.03, a current ratio of 5.59 and a quick ratio of 4.77.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on NPCE. UBS Group began coverage on NeuroPace in a report on Tuesday, January 21st. They issued a “buy” rating and a $17.00 price objective on the stock. JPMorgan Chase & Co. boosted their target price on NeuroPace from $9.00 to $14.00 and gave the stock an “overweight” rating in a report on Tuesday, December 17th. Finally, Wells Fargo & Company boosted their target price on NeuroPace from $13.00 to $17.00 and gave the stock an “overweight” rating in a report on Thursday, January 30th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $14.80.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in NPCE. KCK LTD. purchased a new stake in shares of NeuroPace during the 4th quarter valued at approximately $58,981,000. Jane Street Group LLC purchased a new stake in shares of NeuroPace during the 4th quarter valued at approximately $1,120,000. Jacobs Levy Equity Management Inc. purchased a new stake in shares of NeuroPace during the 4th quarter valued at approximately $639,000. JPMorgan Chase & Co. raised its position in shares of NeuroPace by 440.4% during the 4th quarter. JPMorgan Chase & Co. now owns 64,826 shares of the company’s stock valued at $725,000 after buying an additional 52,829 shares during the period. Finally, Point72 Asset Management L.P. purchased a new stake in shares of NeuroPace during the 4th quarter valued at approximately $369,000. 78.83% of the stock is currently owned by institutional investors and hedge funds.

NeuroPace Company Profile

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.